Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003446priorityCriticalpatent/ECSP003446A/en
Publication of ECSP003446ApublicationCriticalpatent/ECSP003446A/en
Se decsriben los métodos para tratar pacientes que tienen infecciones virales susceptibles, especialmente la infección por hepatitis C crónica administrando a dicho paciente una cantidad terapéuticamente efectiva de una terapia de combinación de interferón-alfa y ravabirina durante un periodo suficiente como para bajar el VHC-ARN asociado con una cantidad terapéuticamente efectiva de un antioxidante durante un periodo suficiente como para mejorar la hemólisis relacionada con la ribavirina.Methods of treating patients who have susceptible viral infections, especially chronic hepatitis C infection, are described by administering to that patient a therapeutically effective amount of a combination therapy with interferon-alpha and ravabirin for a period sufficient to lower HCV-RNA associated with a therapeutically effective amount of an antioxidant for a period sufficient to improve ribavirin-related hemolysis.
ECSP0034462000-04-272000-04-27
COMBINATION THERAPY FOR HCV
ECSP003446A
(en)
COMBINATION THERAPY THAT UNDERSTANDS RIBAVIRINA AND INTERFERED ALPHA IN PATIENTS WHO HAVE NOT BEEN SUBJECTED TO ANTIVIRAL TREATMENT AND HAVE CHRONIC HEPATITIS C INFECTION.
Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin